Global Convalescent Plasma Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Antibody Type;
IgM, IgG, and IgA.By Application;
Prophylaxis and Treatment.By End User;
Hospitals & Clinics, and Laboratories & Research Institutes.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Convalescent Plasma Therapy Market (USD Million), 2021 - 2031
In the year 2024, the Global Convalescent Plasma Therapy Market was valued at USD 3.43 million. The size of this market is expected to increase to USD 9.71 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 16.0%.
The Convalescent Plasma Therapy Market is anticipated to achieve significant revenue growth and an impressive compound annual growth rate (CAGR) from 2023 to 2030. This market expansion is driven by the increasing global demand for Convalescent Plasma Therapy in both prophylaxis and treatment applications. The report provides detailed insights into the lucrative opportunities available at the country level within this market. Additionally, it offers a thorough analysis of costs, market segments, trends, regional developments, and the commercial progress of major key players worldwide during the forecast period.
This Convalescent Plasma Therapy Market report consolidates comprehensive information about the industry, encompassing both quantitative and qualitative data analysis with projections extending from 2023 to 2030. It considers various influencing factors, including product pricing, penetration levels of products or services at both country and regional scales, national GDP, market dynamics within primary and secondary markets, end-use industries, major players, consumer purchasing behavior, and the economic, political, and social conditions of different countries. The report is segmented to provide a detailed examination of the market from multiple perspectives.
The report's primary sections include market segments, market outlook, competitive landscape, and company profiles. Each segment offers in-depth details based on various perspectives such as end-use industry, product or service type, and other relevant criteria reflecting the current market scenario. The market outlook section provides a comprehensive analysis of market evolution, growth drivers, restraints, opportunities, and challenges. It also includes Porter’s Five Forces Framework, macroeconomic analysis, value chain analysis, and pricing analysis, all of which significantly influence the market both presently and throughout the forecast period. The section on drivers and restraints addresses internal market factors, while opportunities and challenges focus on external influences affecting the market. Moreover, the market outlook highlights trends that impact new business development and investment opportunities.
Global Convalescent Plasma Therapy Market Recent Developments
-
Convalescent plasma therapy has shown promising results in clinical trials, demonstrating a potential to reduce mortality rates and improve recovery outcomes, especially in COVID-19 cases. The effectiveness and safety of the therapy in reducing symptoms and boosting recovery have led to increased confidence and wider adoption in hospitals and healthcare settings globally.
-
In August 2020, the U.S. FDA issued an EUA for COVID-19 convalescent plasma, allowing healthcare providers to treat patients hospitalized with COVID-19. However, the authorization faced challenges due to mixed trial results regarding its efficacy.
Segment Analysis
The global convalescent plasma therapy market is growing steadily due to the increasing recognition of the treatment's potential in combating viral infections, particularly in the wake of the COVID-19 pandemic. Convalescent plasma, derived from individuals who have recovered from an infectious disease, contains antibodies that can help boost the immune response in patients who are actively battling the same infection. This therapy has gained significant attention for its role in treating viral diseases, especially during the early phases of the COVID-19 outbreak, when no approved treatments were available. The market is driven by a growing number of clinical studies and trials exploring the effectiveness of convalescent plasma against various infectious diseases, such as Ebola, influenza, and respiratory infections. As researchers continue to evaluate its clinical applications, the demand for plasma-based therapies is expected to expand, positioning convalescent plasma as a critical component of the global therapeutic arsenal.
The market is also segmented by disease type, with convalescent plasma therapy being evaluated and utilized for various viral infections. The COVID-19 pandemic significantly boosted the use of convalescent plasma, with numerous health organizations and government agencies supporting its use as an emergency treatment option for severely ill patients. Although its widespread use has decreased with the approval of other antiviral treatments and vaccines, the legacy of the pandemic has positioned convalescent plasma therapy as a viable treatment option for future viral outbreaks. Additionally, other viral infections, such as Ebola, influenza, and Hepatitis C, continue to drive the demand for plasma therapies. Ongoing research into these diseases suggests that convalescent plasma could offer valuable support in treating patients who have not responded to other forms of treatment, further cementing its role in the global healthcare system.
In terms of distribution channels, the market is influenced by the growing reliance on blood banks, hospitals, and plasma collection centers. Blood banks are central to the collection, processing, and distribution of convalescent plasma, ensuring that the plasma is safe for use in therapeutic applications. Hospitals, where critical care units and emergency departments are primary sites for treating severe infectious diseases, are also major players in administering convalescent plasma. Plasma collection centers are increasingly being seen as key partners in the supply chain, as they facilitate the donation process and ensure the availability of high-quality plasma. The regulatory environment plays a crucial role in shaping the market as well, with governments and health authorities setting guidelines for plasma collection, storage, and transfusion. As more countries establish plasma donation programs and implement standards for safe administration, the global market for convalescent plasma therapy is poised for continued growth, driven by a strong infrastructure and increasing recognition of its potential therapeutic benefits.
Global Convalescent Plasma Therapy Segment Analysis
In this report, the Global Convalescent Plasma Therapy Market has been segmented by Antibody Type, Application, End User, and Geography.
Global Convalescent Plasma Therapy Market, Segmentation by Antibody Type
The Global Convalescent Plasma Therapy Market has been segmented by Antibody Type into IgM, IgG, and IgA.
Their presence in convalescent plasma can be crucial for immediate neutralization of pathogens, making them valuable in acute phase treatments where rapid response is critical. The demand for IgM-rich plasma is particularly high during the initial stages of infectious outbreaks, where quick intervention can prevent disease progression and reduce transmission rates.
IgG and IgA antibodies, on the other hand, play significant roles in longer-term immunity. IgG antibodies are the most abundant and provide lasting protection by neutralizing pathogens and aiding in their clearance from the body. They are crucial for both prophylactic and therapeutic applications, ensuring sustained immune defense. IgA antibodies, primarily found in mucous membranes, provide localized immunity, especially important for infections affecting respiratory and gastrointestinal tracts. This segmentation allows for a targeted approach in plasma therapy, optimizing treatment protocols based on the specific antibody type needed for different stages of infection and types of pathogens, thereby enhancing overall therapeutic efficacy and patient outcomes.
Global Convalescent Plasma Therapy Market, Segmentation by Application
The Global Convalescent Plasma Therapy Market has been segmented by Application into Prophylaxis and Treatment.
The prophylaxis segment involves using convalescent plasma to prevent infection in high-risk populations, such as healthcare workers, immunocompromised individuals, and those with significant exposure to infectious agents. This application aims to provide passive immunity by transferring antibodies from recovered patients to those at risk, thereby reducing the likelihood of infection and its potential complications. The increasing emphasis on preventive healthcare and the urgent need to protect vulnerable populations during outbreaks drive the demand in this segment.
The treatment segment focuses on therapeutic interventions for patients who have already contracted the infection. Convalescent plasma therapy in this context aims to mitigate the severity of the disease, enhance patient recovery, and reduce mortality rates. This application has gained significant attention during pandemics, such as COVID-19, where convalescent plasma was used to treat severe cases. The growing body of clinical evidence supporting its efficacy, coupled with advancements in plasma collection and transfusion technologies, is expected to propel the growth of the treatment segment. This segmentation allows for a targeted analysis of market trends and opportunities, helping stakeholders to develop specific strategies for each application area.
Global Convalescent Plasma Therapy Market, Segmentation by End User
The Global Convalescent Plasma Therapy Market has been segmented by End User into Hospitals & Clinics, and Laboratories & Research institutes.
Hospitals and clinics are the primary end-users of convalescent plasma therapy, as they are the frontline facilities for treating patients with severe infections. These institutions utilize convalescent plasma for both prophylactic and therapeutic purposes, aiming to prevent the spread of infectious diseases among high-risk patients and treat those who have contracted severe infections. The high demand for convalescent plasma in clinical settings is driven by the need for effective treatments during health crises and the ongoing need for transfusion services in managing infectious diseases.
Laboratories and research institutes represent the other critical segment, playing a vital role in the development, testing, and refinement of convalescent plasma therapies. These institutions conduct essential research to understand the efficacy, safety, and mechanisms of action of convalescent plasma in treating various infectious diseases. They are also involved in clinical trials and the development of protocols for plasma collection, storage, and transfusion. The work done by laboratories and research institutes is crucial for advancing medical knowledge and improving therapeutic outcomes, making this segment integral to the overall growth and innovation in the convalescent plasma therapy market.
Global Convalescent Plasma Therapy Market, Segmentation by Geography
In this report, the Global Convalescent Plasma Therapy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Convalescent Plasma Therapy Market Share (%), by Geographical Region, 2024
North America and Europe are expected to dominate the market due to their robust healthcare systems, significant investments in research and development, and high adoption rates of advanced medical therapies. These regions also benefit from strong regulatory frameworks and substantial funding for clinical trials and public health initiatives.
Asia Pacific, the Middle East and Africa, and Latin America are also anticipated to exhibit significant market growth, driven by increasing healthcare awareness, improving medical facilities, and rising incidences of infectious diseases. In the Asia Pacific region, countries like China and India are investing heavily in healthcare infrastructure and research capabilities, which is propelling the market forward. Similarly, in the Middle East and Africa, efforts to enhance healthcare access and disease management are creating new opportunities for market expansion. Latin America is also experiencing growth due to government initiatives aimed at improving healthcare services and increasing access to advanced treatments. This geographical segmentation allows for a detailed analysis of regional trends, challenges, and opportunities, enabling stakeholders to tailor strategies to specific market needs and conditions.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Convalescent Plasma Therapy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers :
- Rising incidence of infectious diseases
- Growing awareness and government support
-
Limited treatment options for certain diseases - The Global Convalescent Plasma Therapy Market is significantly impacted by the limited treatment options available for certain diseases, particularly emerging infectious diseases and conditions where standard treatments are ineffective. Convalescent plasma therapy offers a critical alternative for these scenarios, utilizing antibodies from recovered patients to combat active infections in others. This approach is particularly valuable in situations where antiviral drugs or vaccines are not yet available, providing a stopgap solution that can reduce disease severity and improve patient outcomes. The reliance on convalescent plasma therapy in such cases underscores its importance as a therapeutic option and drives demand within the market.
The dependence on convalescent plasma therapy also highlights several challenges, including the variability in antibody quality and quantity from different donors, logistical complexities in plasma collection and storage, and the need for rapid mobilization during outbreaks. Moreover, as a biologic treatment, it requires stringent regulatory oversight and robust clinical protocols to ensure safety and efficacy. Despite these challenges, the urgent need for effective treatments in the face of limited alternatives continues to propel the growth of the convalescent plasma therapy market, fostering innovation and improvements in plasma therapy techniques and infrastructure. This dynamic underscores the market's potential to address critical healthcare gaps while highlighting areas for ongoing development and optimization.
Restraints :
- Limited efficacy and safety concerns
- Stringent regulatory requirements
-
Logistics and donor availability - The logistics and donor availability are critical components shaping the Global Convalescent Plasma Therapy Market. Efficient logistics systems are essential for the collection, storage, and transportation of convalescent plasma to ensure its efficacy and safety. This involves maintaining cold chain logistics, proper labeling, and timely distribution to healthcare facilities. Any disruptions in the supply chain can significantly impact the availability and effectiveness of the therapy. Moreover, the integration of advanced technologies for plasma screening and tracking is enhancing the reliability of logistics operations, ensuring that the plasma remains viable from donation to transfusion.
Donor availability is another crucial factor influencing the market. The success of convalescent plasma therapy depends on a steady supply of plasma from recovered patients who have developed the necessary antibodies. Public awareness campaigns, incentives for donors, and streamlined donation processes are vital to maintaining an adequate donor pool. Additionally, the establishment of donor registries and collaboration with blood banks and health organizations are essential strategies to ensure a consistent and reliable supply. Challenges such as donor eligibility criteria, varying recovery rates, and geographical disparities in donor availability need to be addressed to optimize the donor base and meet the growing demand for convalescent plasma therapy globally.
Opportunities :
- Technological advancements
- Development of new applications
-
Increasing focus on personalized medicine - The Global Convalescent Plasma Therapy Market is experiencing significant growth due to an increasing focus on personalized medicine. Personalized medicine tailors medical treatment to the individual characteristics of each patient, and convalescent plasma therapy fits well into this paradigm by using plasma from recovered individuals whose antibodies are specifically suited to combat the pathogens in the recipient's body. This targeted approach enhances the efficacy of the treatment, providing a more effective and personalized therapeutic option for patients suffering from infectious diseases. The ability to match plasma donors and recipients based on specific antibody profiles can lead to better outcomes and faster recovery times.
Advancements in genomic and proteomic technologies are facilitating the identification of optimal donors and the precise measurement of antibody levels and specificities, which is crucial for the success of personalized plasma therapy. The growing database of immunological profiles from recovered patients allows for a more strategic selection of plasma, aligning with the principles of personalized medicine. This shift towards personalized treatment is not only improving patient outcomes but also driving innovation and investment in the convalescent plasma therapy market, as stakeholders recognize the potential for tailored therapies to address complex and diverse healthcare challenges.
Competitive Landscape Analysis
Key players in Global Convalescent Plasma Therapy Market include;
- Bio Farma
- Grifols
- Hilton Pharma
- Biotest
- BPL
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Antibody Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Convalescent Plasma Therapy Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising incidence of infectious diseases
- Growing awareness and government support
- Limited treatment options for certain diseases
- Restraints
- Limited efficacy and safety concerns
- Stringent regulatory requirements
- Logistics and donor availability
- Opportunities
- Technological advancements
- Development of new applications
- Increasing focus on personalized medicine
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
-
Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Convalescent Plasma Therapy Market, By Antibody Type, 2021 - 2031 (USD Million)
- IgM
- IgG
- IgA
- Global Convalescent Plasma Therapy Market, By Application, 2021 - 2031 (USD Million)
- Prophylaxis
- Treatment
- Global Convalescent Plasma Therapy Market, By End User, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Laboratories & Research institutes
- Global Convalescent Plasma Therapy Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Convalescent Plasma Therapy Market, By Antibody Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Bio Farma
- Grifols
- Hilton Pharma
- Biotest
- BPL
- Company Profiles
- Analyst Views
- Future Outlook of the Market